Report by : Gan Yung Chyan
/ KUCINTA SETIA
Images courtesy : Chinese Life Network
On 16 May 2020, a California biopharmaceutical company headquartered in San Diego, Sorrento Therapeutics, Inc., said it discovered an antibody STI-1499 that protects the body from infection with SARS-CoV-2 (covi, in short) and removes the virus from the human system within 4 days. The antibody is independent and a part of a planned mixture of three antibodies per dose known as "antibody cocktail".
The antibody STI-1499 can "100% inhibit" covi, establish a defense barrier in the human body within 4 days, isolate the coronavirus, and discharge it from the human system.
Dr. Henry Ji, founder and CEO of Sorrento, said, "We want to emphasize that there is a treatment that can be 100% effective and can be months before the vaccine is launched."
Sorrento Therapeutics, Inc., founded in 2006, is headquartered in San Diego, California, USA, with 382 full-time employees. It is a clinical stage biopharmaceutical company. It mainly engages in the discovery and development of oncology treatment and global chronic cancer pain treatment.
According to Sorrento Therapeutics, Inc. it is developing the STI-1499 antibody therapy known as "Antibody Cocktail" in collaboration with Mount Sinai Medical School in New York.
Why take such a name? It is because it provides a mixture of three antibodies per dose, slightly like a cocktail.
At present, the discovered STI-1499 is the first antibody in the cocktail.
According to a statement provided by Sorrento Therapeutics, Inc. to Fox News, because the antibody is too bovine X, they also developed it as an independent therapy.
Before the antibody therapy was developed, plasma therapy was regarded as one of the only important treatments that could directly and effectively save critically ill patients.
The plasma of covid recoverers contains a variety of natural antibodies, which can be used to treat patients who have not produced enough antibodies.
Although plasma therapy seems to be effective, there are actually many uncertainties.
The principle of this treatment is that when the virus infects the human body, the body's immune system responds to the invading virus, and the activated B cells produce antibodies and release them into the blood.
When the patient recovers, his serum or plasma contains antibodies against the virus, and plasma therapy is essentially antibody therapy.
The pathogen of rapid proliferation and replication of covi will interact with the body in a very complex and dynamic manner.
Plasma treatment is no longer a simple problem of antibody neutralization of toxins, and it is also difficult to intervene at different stages of infection.
In addition, there are problems such as limited sources of therapeutic plasma, different antibody concentrations and activities in different human plasmas, and non-neutralizing antibodies in plasma that may contribute to cytokine storms and other safety risks.
Therefore, the plasma therapy in the recovery period is only used on a small scale, and the large-scale use still needs to look at the effects and adverse reactions of clinical application.
In the absence of vaccines and special treatment drugs, plasma therapy in the recovery period can be regarded as an exploratory treatment.
Dr. Ji said, "When antibodies prevent viruses from entering human cells, viruses will not survive." "If they cannot enter cells, they will not replicate, and eventually they will die and the body will clear the virus."
Because there are no side effects, this time the antibody can be used as a preventive therapy, and it may be more effective than any vaccines that have been developed.
The purpose of making vaccines is to let people produce antibodies through vaccines. If a person has already had antibodies, vaccines are not needed.
Sorrento Therapeutics, Inc. looks forward to FDA approval of the antibody therapy as soon as possible. They said in a statement that they can produce up to 200,000 doses of antibodies per month, which will be months before the SARS-CoV-2 vaccine is launched.
However, the application of antibody therapy within a few months requires rapid approval by the FDA.
Dr Brunswick said, "Once the antibody is injected, the patient is immediately immunized against the new crown, and there is no need to worry about COVID-19 infection. If approved by the FDA, preparations for resumption of work can be done."
About Sorrento Therapeutics Inc.'s founder
Sorrento Therapeutics Inc.'s founder and CEO is Henry Ji Hongjun, a Chinese. He holds a Ph.D. and graduated from Shanghai Fudan University with a major in biochemistry.
Soon, he achieved excellent results in college. He graduated from the University of Minnesota in Animal Physiology. After graduating with a doctorate, he decided to devote himself to the research of biopharmaceuticals.
To start a business in the US, Henry Ji found a cheap place to rent a garage to use as his standard laboratory, and started his biopharmaceutical research career here. The laboratory is about 100 square metres, and it takes 5 years for him to start a business.
During these five years, he often read a large number of financial investment books and learned financial knowledge by himself, and paid too much.
Finally, in time, Ji Hongjun's company was acquired by Angelon in 2001.
Soon, he was very lucky to get a financial support.
In 2006, Dr. Henry Ji founded Sorrento in San Diego.
Today, Sorrento is listed on NASDAQ, and this company is one of the few Chinese-dominated biopharmaceutical companies in the United States. It has established its leading position in cancer immunotherapy, cell therapy, and antibody-drug conjugation.
Sorrento's proprietary G-MAB technology invented by Dr. Henry Ji has successfully identified more than 100 clinically relevant high-impact carcinogenic targets (including PD-1, PD-L1, CD38, CD123) , CD47, c-MET, VEGFR2 and CCR2) fully human antibodies.
The Chinese community in the US hope that this antibody therapy can be approved by the FDA earlier to save the world.
Source : Chinese Life Network
Ref : https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=416943
/ KUCINTA SETIA
Images courtesy : Chinese Life Network
On 16 May 2020, a California biopharmaceutical company headquartered in San Diego, Sorrento Therapeutics, Inc., said it discovered an antibody STI-1499 that protects the body from infection with SARS-CoV-2 (covi, in short) and removes the virus from the human system within 4 days. The antibody is independent and a part of a planned mixture of three antibodies per dose known as "antibody cocktail".
The antibody STI-1499 can "100% inhibit" covi, establish a defense barrier in the human body within 4 days, isolate the coronavirus, and discharge it from the human system.
Dr. Henry Ji, founder and CEO of Sorrento, said, "We want to emphasize that there is a treatment that can be 100% effective and can be months before the vaccine is launched."
Sorrento Therapeutics, Inc., founded in 2006, is headquartered in San Diego, California, USA, with 382 full-time employees. It is a clinical stage biopharmaceutical company. It mainly engages in the discovery and development of oncology treatment and global chronic cancer pain treatment.
According to Sorrento Therapeutics, Inc. it is developing the STI-1499 antibody therapy known as "Antibody Cocktail" in collaboration with Mount Sinai Medical School in New York.
Why take such a name? It is because it provides a mixture of three antibodies per dose, slightly like a cocktail.
At present, the discovered STI-1499 is the first antibody in the cocktail.
According to a statement provided by Sorrento Therapeutics, Inc. to Fox News, because the antibody is too bovine X, they also developed it as an independent therapy.
Before the antibody therapy was developed, plasma therapy was regarded as one of the only important treatments that could directly and effectively save critically ill patients.
The plasma of covid recoverers contains a variety of natural antibodies, which can be used to treat patients who have not produced enough antibodies.
Although plasma therapy seems to be effective, there are actually many uncertainties.
The principle of this treatment is that when the virus infects the human body, the body's immune system responds to the invading virus, and the activated B cells produce antibodies and release them into the blood.
When the patient recovers, his serum or plasma contains antibodies against the virus, and plasma therapy is essentially antibody therapy.
The pathogen of rapid proliferation and replication of covi will interact with the body in a very complex and dynamic manner.
Plasma treatment is no longer a simple problem of antibody neutralization of toxins, and it is also difficult to intervene at different stages of infection.
In addition, there are problems such as limited sources of therapeutic plasma, different antibody concentrations and activities in different human plasmas, and non-neutralizing antibodies in plasma that may contribute to cytokine storms and other safety risks.
Therefore, the plasma therapy in the recovery period is only used on a small scale, and the large-scale use still needs to look at the effects and adverse reactions of clinical application.
In the absence of vaccines and special treatment drugs, plasma therapy in the recovery period can be regarded as an exploratory treatment.
Dr. Ji said, "When antibodies prevent viruses from entering human cells, viruses will not survive." "If they cannot enter cells, they will not replicate, and eventually they will die and the body will clear the virus."
Because there are no side effects, this time the antibody can be used as a preventive therapy, and it may be more effective than any vaccines that have been developed.
The purpose of making vaccines is to let people produce antibodies through vaccines. If a person has already had antibodies, vaccines are not needed.
Sorrento Therapeutics, Inc. looks forward to FDA approval of the antibody therapy as soon as possible. They said in a statement that they can produce up to 200,000 doses of antibodies per month, which will be months before the SARS-CoV-2 vaccine is launched.
However, the application of antibody therapy within a few months requires rapid approval by the FDA.
Dr Brunswick said, "Once the antibody is injected, the patient is immediately immunized against the new crown, and there is no need to worry about COVID-19 infection. If approved by the FDA, preparations for resumption of work can be done."
About Sorrento Therapeutics Inc.'s founder
Sorrento Therapeutics Inc.'s founder and CEO is Henry Ji Hongjun, a Chinese. He holds a Ph.D. and graduated from Shanghai Fudan University with a major in biochemistry.
Soon, he achieved excellent results in college. He graduated from the University of Minnesota in Animal Physiology. After graduating with a doctorate, he decided to devote himself to the research of biopharmaceuticals.
To start a business in the US, Henry Ji found a cheap place to rent a garage to use as his standard laboratory, and started his biopharmaceutical research career here. The laboratory is about 100 square metres, and it takes 5 years for him to start a business.
During these five years, he often read a large number of financial investment books and learned financial knowledge by himself, and paid too much.
Finally, in time, Ji Hongjun's company was acquired by Angelon in 2001.
Soon, he was very lucky to get a financial support.
In 2006, Dr. Henry Ji founded Sorrento in San Diego.
Today, Sorrento is listed on NASDAQ, and this company is one of the few Chinese-dominated biopharmaceutical companies in the United States. It has established its leading position in cancer immunotherapy, cell therapy, and antibody-drug conjugation.
Sorrento's proprietary G-MAB technology invented by Dr. Henry Ji has successfully identified more than 100 clinically relevant high-impact carcinogenic targets (including PD-1, PD-L1, CD38, CD123) , CD47, c-MET, VEGFR2 and CCR2) fully human antibodies.
The Chinese community in the US hope that this antibody therapy can be approved by the FDA earlier to save the world.
Source : Chinese Life Network
Ref : https://www.6parknews.com/newspark/view.php?app=news&act=view&nid=416943
No comments:
Post a Comment